30 closest matches · ranked by relevance
Childhood Acute Promyelocytic Leukemia With PML-RARA · Myeloid Neoplasm
Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants
Leukemia
Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05
Acute Promyelocytic Leukemia
Primary: Complete Response (CR) Rate — 55; 5; 15 Participants
Leukemia
Primary: Continuous Complete Remission at 3 Years — 74 percentage of participants
Acute Promyelocytic Leukemia
Primary: To Determine the Rate of Molecular Remission
Leukemia
Primary: 3-year Disease-free Survival (DFS) Rate — 96; 100 percentage of patients
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Myelodysplastic Syndrome · Acute Myelogenous Leukemia
Primary: Number of Participants With Response — 12; 3; 7 Participants
Leukemia, Myelocytic, Acute
Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 45 participants
Acute Myeloid Leukemia
Primary: Occurrence of Dose Limiting Toxicities — 0; 0; 0 participants
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Participants Complete Response — 9 Participants
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Primary: To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT). — 12.5 months
Leukemia
Primary: Complete Remission (CR) — 77; 32; 2 Participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Acute Myelogenous Leukemia · Myelodysplastic Syndrome · Leukemia
Primary: Number of Participants With Response — 0; 0; 4; 5 Participants
Acute Myelogenous Leukemia
Primary: Progression Free Survival — 21 days
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 24; 29 participants
Acute Myeloid Leukemia
Primary: Number of Participants With Cardiac Toxicity, Defined as Reduction in LVEF of >= 10% Compared to Baseline LVEF and EF =< 50% on the Follow-up Scan, Assessed Using MRI…
Refractory Leukemia · Acute Myelogenous Leukemia
Primary: Best Response as Per Investigator Assessment by Stratum (FAS) — 3.1; 7.4; 0; 3.7 Percentage of Participants
Leukemia · Acute Myeloid Leukemia · AML
Primary: Complete Response (CR) Rate — 98; 4; 9; 7 Participants
AML
Primary: Complete Response Rate — 19 Participants
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants
Acute Myeloid Leukemia
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Peg-IFN-α — 180 mcg